| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Characteristics of clinical trials for haematological malignancies from 2015 to 2020: A systematic review
|
Wesson, William
|
|
|
167 |
C |
p. 152-160
|
artikel
|
| 2 |
Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020–Sep 2020; Sep 2020–May 2021) in the Veneto Oncology Network: The ROVID study
|
Dieci, Maria V.
|
|
|
167 |
C |
p. 81-91
|
artikel
|
| 3 |
Contemporary clinical trials in hematologic cancer: Have we forgotten where we came from?
|
Sengar, Manju
|
|
|
167 |
C |
p. 161-163
|
artikel
|
| 4 |
C-reactive protein flare predicts response to anti-PD-(L)1 immune checkpoint blockade in metastatic urothelial carcinoma
|
Klümper, Niklas
|
|
|
167 |
C |
p. 13-22
|
artikel
|
| 5 |
Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations
|
Riudavets, Mariona
|
|
|
167 |
C |
p. 142-148
|
artikel
|
| 6 |
Effect of the time interval between melanoma diagnosis and sentinel node biopsy on the size of metastatic tumour deposits in node-positive patients
|
El Sharouni, Mary-Ann
|
|
|
167 |
C |
p. 133-141
|
artikel
|
| 7 |
Explainable artificial intelligence in skin cancer recognition: A systematic review
|
Hauser, Katja
|
|
|
167 |
C |
p. 54-69
|
artikel
|
| 8 |
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies
|
Antoniotti, Carlotta
|
|
|
167 |
C |
p. 23-31
|
artikel
|
| 9 |
Keratinocyte apoptosis was present in clinically intact skin in a patient treated with enfortumab vedotin
|
Oya, Kazumasa
|
|
|
167 |
C |
p. 172-174
|
artikel
|
| 10 |
Life-threatening skin reaction with Enfortumab Vedotin: Six cases
|
Guerrois, Florine
|
|
|
167 |
C |
p. 168-171
|
artikel
|
| 11 |
MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma – An evaluation of the multicenter prospective skin cancer registry ADOREG
|
Kreft, Sophia
|
|
|
167 |
C |
p. 32-41
|
artikel
|
| 12 |
Pembrolizumab and maraviroc in refractory mismatch repair proficient/microsatellite-stable metastatic colorectal cancer – The PICCASSO phase I trial
|
Haag, Georg Martin
|
|
|
167 |
C |
p. 112-122
|
artikel
|
| 13 |
Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs
|
Guiard, Emeline
|
|
|
167 |
C |
p. 42-53
|
artikel
|
| 14 |
Re: Androgen deprivation therapy and radiotherapy in intermediate risk prostate cancer: A randomized phase III trial
|
Guler, Ozan Cem
|
|
|
167 |
C |
p. 164-165
|
artikel
|
| 15 |
Reply to comment on: Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial
|
Nabid, Abdenour
|
|
|
167 |
C |
p. 166-167
|
artikel
|
| 16 |
Response to immune checkpoint inhibitors in acral melanoma: A nationwide cohort study
|
van Not, Olivier J.
|
|
|
167 |
C |
p. 70-80
|
artikel
|
| 17 |
Seroconversion after SARS-CoV-2 mRNA booster vaccine in cancer patients
|
Patelli, Giorgio
|
|
|
167 |
C |
p. 175-176
|
artikel
|
| 18 |
The gap between rare and common cancers still exists: Results from a population-based study in the Netherlands
|
de Heus, Eline
|
|
|
167 |
C |
p. 103-111
|
artikel
|
| 19 |
Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes
|
El Sharouni, Mary-Ann
|
|
|
167 |
C |
p. 123-132
|
artikel
|
| 20 |
Treatment response and 5-year distant metastasis-free survival outcome in breast cancer patients after the use of MammaPrint and BluePrint to guide preoperative systemic treatment decisions
|
Göker, Emine
|
|
|
167 |
C |
p. 92-102
|
artikel
|
| 21 |
Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib
|
Kudo, Masatoshi
|
|
|
167 |
C |
p. 1-12
|
artikel
|
| 22 |
Who benefits from consolidation durvalumab in stage III non-small cell lung cancer?
|
De Ruysscher, Dirk
|
|
|
167 |
C |
p. 149-151
|
artikel
|
Tijdschrift beschrijving